Consistently, mavorixafor, an oral CXCR4 antagonist, increases the absolute number of lymphocytes and may improve the infection rate in WHIM, but the specific effect on the humoral response is not known at present (Dale et al, 2020; Badolato & Donadieu, 2023). This evidence concerns the gene CXCR4 and infection.